Clinical and experimental evidence indicates that estrogens are involved in the control of hepatocyte proliferation both in normal and in neoplastic conditions. Thirty-two cirrhotic patients with unresectable or otherwise untreatable hepatocellular carcinoma were allocated to receive either tamoxifen (30 mg/day) or no treatment. The patients in the two groups were matched for age, male/female ratio, Child-Pugh class, approximate tumor volume (US and CT scan), and etiology of the underlying cirrhosis. Survival of the tamoxifen-treated patients (life-table, Wilcoxon-Breslow) was significantly prolonged (P = 0.0038), with 35% (vs 0%) survival at 12 months. No difference was observed between males and females or between alcoholic and nonalcoholic cirrhosis. In 40% of tamoxifen-treated patients, the levels of alpha-fetoprotein declined. In conclusion, the antiestrogen tamoxifen appears to be effective in the palliative treatment of hepatocellular carcinoma. An initial decline in alpha-fetoprotein levels may represent an early favorable prognostic sign

Farinati, F., De Maria, N., Fornasiero, A., Salvagnini, M., Fagiuoli, S., Chiaramonte, M., et al. (1992). Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. DIGESTIVE DISEASES AND SCIENCES, 37(5), 659-662 [10.1007/BF01296419].

Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma

Fagiuoli S;
1992

Abstract

Clinical and experimental evidence indicates that estrogens are involved in the control of hepatocyte proliferation both in normal and in neoplastic conditions. Thirty-two cirrhotic patients with unresectable or otherwise untreatable hepatocellular carcinoma were allocated to receive either tamoxifen (30 mg/day) or no treatment. The patients in the two groups were matched for age, male/female ratio, Child-Pugh class, approximate tumor volume (US and CT scan), and etiology of the underlying cirrhosis. Survival of the tamoxifen-treated patients (life-table, Wilcoxon-Breslow) was significantly prolonged (P = 0.0038), with 35% (vs 0%) survival at 12 months. No difference was observed between males and females or between alcoholic and nonalcoholic cirrhosis. In 40% of tamoxifen-treated patients, the levels of alpha-fetoprotein declined. In conclusion, the antiestrogen tamoxifen appears to be effective in the palliative treatment of hepatocellular carcinoma. An initial decline in alpha-fetoprotein levels may represent an early favorable prognostic sign
Articolo in rivista - Articolo scientifico
estrogens; hepatocellular carcinoma; hormones; liver neoplasmas;
English
659
662
4
Farinati, F., De Maria, N., Fornasiero, A., Salvagnini, M., Fagiuoli, S., Chiaramonte, M., et al. (1992). Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. DIGESTIVE DISEASES AND SCIENCES, 37(5), 659-662 [10.1007/BF01296419].
Farinati, F; De Maria, N; Fornasiero, A; Salvagnini, M; Fagiuoli, S; Chiaramonte, M; Naccarato, R
File in questo prodotto:
File Dimensione Formato  
Farinati F. (1992) Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma.pdf

Solo gestori archivio

Dimensione 2.27 MB
Formato Adobe PDF
2.27 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353223
Citazioni
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 63
Social impact